REMAPCAP

The inter-pandemic focus was on finding the best treatment CAP, the disease most likely to resemble a pandemic disease with major effects on hospitalized patients, including the most critically ill. REMAP-CAP was designed to adapt to a future pandemic since its inception... Adaptive platform trials, specifically REMAP-CAP, help overcome the challenges of pandemic research. They approach research from the perspective of the disease, rather than a single treatment. This aligns with clinical care, where hospitalized patients with CAP (including COVID-19) are treated with a combination of treatments rather than a single drug. This leads to faster learning, and incorporates learning about potential interactions between treatments... REMAP-CAP is supported by the ECRAID-Base project which has received funding from the EU Horizon 2020 research and innovation programme (grant number 965313).

Primary location: Utrecht Netherlands